<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114255</article-id><article-id pub-id-type="publisher-id">ACM-41765</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_90898137.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  血小板与淋巴细胞比值和单核细胞与淋巴细胞比值预测脓毒症患者发生急性肾损伤的价值
  Predictive Value of Platelet-to-Lymphocyte Ratio and Monocyte-to-Lymphocyte Ratio in Acute Kidney Injury of Patients with Sepsis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>猛</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姜</surname><given-names>丽莉</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>齐</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>连弟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院重症医学科，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>海阳市人民医院检验科，山东 烟台</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1774</fpage><lpage>1781</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探索血小板与淋巴细胞比值(PLR)和单核细胞与淋巴细胞比值(MLR)预测脓毒症患者发生急性肾损伤(AKI)的价值。方法：将221例脓毒症患者分为AKI组和非AKI组(N-AKI组)，对两组患者入院时的PLR、MLR和相关的临床指标进行统计分析；采用Spearman相关性分析对PLR、MLR与其他的临床指标进行相关性分析；采用Logistic回归模型及ROC曲线分析，探讨入院时PLR、MLR对脓毒症患者发生急性肾损伤的预测价值。结果：AKI组患者入院时的PLR、MLR均小于N-AKI组，差异有统计学意义(P &lt; 0.001)；入院时的PLR、MLR与SOFA评分呈显著负相关(P &lt; 0.05)；多因素Logistic回归分析显示PLR、MLR、动脉血乳酸、APACHEⅡ评分、SOFA评分均为脓毒症患者发生AKI的独立预测因素；PLR预测脓毒症患者发生AKI的AUC为0.646，最佳截断值为127.875，敏感度48.4%，特异性77%。MLR预测脓毒症患者发生AKI的AUC为0.638，最佳截断值为0.455，敏感度53.7%，特异性69.8%。结论：PLR、MLR可以作为预测脓毒症患者发生AKI的有效指标。
    Objective: To explore the value of platelet-to-lymphocyte ratio (PLR) and monocyte-to-lymphocyte ratio (MLR) in predicting acute kidney injury (AKI) in patients with sepsis. Methods: 221 patients with sepsis were divided into AKI group and non-AKI group (N-AKI group). The PLR, MLR and related clinical indicators of the two groups at admission were statistically analyzed. Spearman correlation analysis was used to analyze the correlation between PLR, MLR and other clinical indicators. Logistic regression model and ROC curve analysis were both used to explore the predictive value of PLR and MLR on AKI in sepsis patients. Results: The PLR and MLR at admission in AKI group were lower than those in N-AKI group, the difference was statistically significant (P &lt; 0.001); PLR and MLR at admission were significantly negatively correlated with SOFA score (P &lt; 0.05); multivariate logistic regression analysis showed that PLR, MLR, arterial blood lactic acid, APACHEⅡscore, SOFA score were independent predictors of AKI in sepsis patients; PLR predicted AKI in sepsis patients. The AUC was 0.646, the best cutoff value was 127.875, the sensitivity was 48.4%, and the specificity was 77%. The AUC of MLR was 0.638, the best cut-off value was 0.455, the sensitivity was 53.7%, and the specificity was 69.8%. Conclusion: PLR and MLR can be used to predict AKI in patients with sepsis. 
  
 
</p></abstract><kwd-group><kwd>血小板与淋巴细胞比值，单核细胞与淋巴细胞比值，脓毒症，急性肾损伤，预测价值, Platelet-to-Lymphocyte Ratio</kwd><kwd> Monocyte-to-Lymphocyte Ratio</kwd><kwd> Sepsis</kwd><kwd> Acute Kidney Injury</kwd><kwd> 
Predictive Value</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探索血小板与淋巴细胞比值(PLR)和单核细胞与淋巴细胞比值(MLR)预测脓毒症患者发生急性肾损伤(AKI)的价值。方法：将221例脓毒症患者分为AKI组和非AKI组(N-AKI组)，对两组患者入院时的PLR、MLR和相关的临床指标进行统计分析；采用Spearman相关性分析对PLR、MLR与其他的临床指标进行相关性分析；采用Logistic回归模型及ROC曲线分析，探讨入院时PLR、MLR对脓毒症患者发生急性肾损伤的预测价值。结果：AKI组患者入院时的PLR、MLR均小于N-AKI组，差异有统计学意义(P &lt; 0.001)；入院时的PLR、MLR与SOFA评分呈显著负相关(P &lt; 0.05)；多因素Logistic回归分析显示PLR、MLR、动脉血乳酸、APACHEⅡ评分、SOFA评分均为脓毒症患者发生AKI的独立预测因素；PLR预测脓毒症患者发生AKI的AUC为0.646，最佳截断值为127.875，敏感度48.4%，特异性77%。MLR预测脓毒症患者发生AKI的AUC为0.638，最佳截断值为0.455，敏感度53.7%，特异性69.8%。结论：PLR、MLR可以作为预测脓毒症患者发生AKI的有效指标。</p></sec><sec id="s2"><title>关键词</title><p>血小板与淋巴细胞比值，单核细胞与淋巴细胞比值，脓毒症，急性肾损伤，预测价值</p></sec><sec id="s3"><title>Predictive Value of Platelet-to-Lymphocyte Ratio and Monocyte-to-Lymphocyte Ratio in Acute Kidney Injury of Patients with Sepsis</title><p>Meng Wang<sup>1</sup>, Lili Jiang<sup>2</sup>, Qi Zhou<sup>2</sup>, Liandi Li<sup>1*</sup></p><p><sup>1</sup>The Affiliated Hospital of Qingdao University Intensive Care Unit, Qingdao Shandong</p><p><sup>2</sup>The People’s Hospital of Haiyang Clinical Laboratory, Yantai Shandong</p><p><img src="//html.hanspub.org/file/48-1572168x5_hanspub.png" /></p><p>Received: Mar. 19<sup>th</sup>, 2021; accepted: Apr. 15<sup>th</sup>, 2021; published: Apr. 22<sup>nd</sup>, 2021</p><p><img src="//html.hanspub.org/file/48-1572168x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the value of platelet-to-lymphocyte ratio (PLR) and monocyte-to-lymphocyte ratio (MLR) in predicting acute kidney injury (AKI) in patients with sepsis. Methods: 221 patients with sepsis were divided into AKI group and non-AKI group (N-AKI group). The PLR, MLR and related clinical indicators of the two groups at admission were statistically analyzed. Spearman correlation analysis was used to analyze the correlation between PLR, MLR and other clinical indicators. Logistic regression model and ROC curve analysis were both used to explore the predictive value of PLR and MLR on AKI in sepsis patients. Results: The PLR and MLR at admission in AKI group were lower than those in N-AKI group, the difference was statistically significant (P &lt; 0.001); PLR and MLR at admission were significantly negatively correlated with SOFA score (P &lt; 0.05); multivariate logistic regression analysis showed that PLR, MLR, arterial blood lactic acid, APACHEⅡscore, SOFA score were independent predictors of AKI in sepsis patients; PLR predicted AKI in sepsis patients. The AUC was 0.646, the best cutoff value was 127.875, the sensitivity was 48.4%, and the specificity was 77%. The AUC of MLR was 0.638, the best cut-off value was 0.455, the sensitivity was 53.7%, and the specificity was 69.8%. Conclusion: PLR and MLR can be used to predict AKI in patients with sepsis.</p><p>Keywords:Platelet-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, Sepsis, Acute Kidney Injury, Predictive Value</p><disp-formula id="hanspub.41765-formula60"><graphic xlink:href="//html.hanspub.org/file/48-1572168x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/48-1572168x8_hanspub.png" /> <img src="//html.hanspub.org/file/48-1572168x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>脓毒症(Sepsis)急性肾损伤(Acute Kidney Injury, AKI)是重症监护室(Intensive Care Unit, ICU)最常见的AKI综合征，与较高的死亡率相关。目前的困难在于预防脓毒症患者发生AKI，因为当患者就医时，大多数已经发展成AKI [<xref ref-type="bibr" rid="hanspub.41765-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.41765-ref2">2</xref>]。因此，早期识别脓毒症AKI，有助于提供支持性治疗和避免肾功能进一步的损伤。目前临床上仍以血清肌酐和尿量作为诊断AKI的指标，由于血清肌酐出现在肾损伤的中晚期，且受肌肉含量、饮食结构等因素的影响。尿量受利尿剂、血管活性药物、液体复苏、血液净化等临床治疗措施的影响，并不能真实地反映出肾脏是否早期受损 [<xref ref-type="bibr" rid="hanspub.41765-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.41765-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.41765-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.41765-ref6">6</xref>]。因此临床需要能够早期、及时、快捷评估脓毒症发生AKI的指标。</p><p>炎症反应是AKI病理生理的重要机制之一 [<xref ref-type="bibr" rid="hanspub.41765-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.41765-ref8">8</xref>]。从各级医院中最普及的血常规中可以非常容易计算出PLR和MLR，因为血小板、单核细胞、淋巴细胞易受生理、病理和物理因素的影响，所以PLR、MLR是更实用的指标 [<xref ref-type="bibr" rid="hanspub.41765-ref9">9</xref>]。本研究探讨了PLR和MLR对脓毒症患者发生AKI的预测价值。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>收集2018年6月~2020年5月期间入住青岛大学附属医院ICU的221例脓毒症患者作为研究对象。</p><p>纳入标准：1) 脓毒症诊断符合《第3次脓毒症和脓毒性休克定义国际共识(Sepsis-3.0)》的标准 [<xref ref-type="bibr" rid="hanspub.41765-ref10">10</xref>]，即感染或疑似感染患者，且序贯器官衰竭(SOFA)评分 ≥ 2分。脓毒性休克：指脓毒症患者在充分液体复苏后仍存在持续性低血压，需要使用血管活性药物维持平均动脉压 ≥ 65 mmHg (1 mmHg = 0.133 kPa)以及血乳酸 &gt; 2 mmol/L。2) 急性肾损伤诊断标准：根据改善全球肾脏病预后组织(KDIGO)指南标准 [<xref ref-type="bibr" rid="hanspub.41765-ref11">11</xref>]，符合以下任意一条即可诊断为AKI：① 在48小时内血肌酐上升 ≥ 26.5 μmoL/L；② 已知或推测肾功能损害发生在7天之内，血肌酐上升至 ≥ 基线值的1.5倍；③ 尿量 &lt; 0.5 ml/(kg&#183;h)，持续6小时。</p><p>排除标准：1) 入院48小时内死亡或自动出院的患者；2) 患者有慢性肾病病史或肾移植病史；3) 入院时使用血液净化疗法；4) 患者存在影响NLR和PLR的疾病，如恶性肿瘤、艾滋病毒感染、自身免疫疾病、血液系统疾病等；5) 合并急性冠脉综合征的患者；6) 孕产妇和临床资料不全的患者。</p></sec><sec id="s6_2"><title>2.2. 资料收集</title><p>通过青岛大学附属医院的医院信息系统，收集患者的一般临床资料如性别、年龄、是否脓毒性休克、是否机械通气、是否血液净化、是否应用血管活性药物等。收集患者入住ICU24小时内首次测得的平均动脉压(mean arterial pressure, MAP)、血尿素氮(blood urea nitrogen, BUN)、血肌酐(serum creatinine, Cr)、白细胞计数(white blood cell, WBC)、单核细胞计数(monocyte, MON)、淋巴细胞计数(lymphocyte LYM)、血小板计数(platelet, PLT)、降钙素原(procalcitonin, PCT)、动脉血pH值(arterial blood pH, pH)、动脉血乳酸(lactate, Lac)、氧合指数(oxygenation index, OI)、急性生理学与慢性健康状况评分系统II (acute physiology and chronic health scoring system II, APACHE II)、序贯器官功能衰竭(sequential organ failure assessment, SOFA)评分。并计算入住ICU时的血小板与淋巴细胞比值(platelet-to-lymphocyte ratio, PLR)、单核细胞与淋巴细胞比值(monocyte-to-lymphocyte ratio, MLR)，中性粒细与淋巴细胞比值(neutrophil-to-lymphocyte ratio, NLR)。</p></sec><sec id="s6_3"><title>2.3. 统计学方法</title><p>采用SPSS26.0进行统计学分析。数据均进行正态性检验及方差齐性检验，正态分布的计量资料统计描述采用均数&#177;标准差( x &#175; &#177; s )表示，组间比较采用独立样本t检验；非正态分布的计量资料统计描述采用中位数(四分位数) [M(P25, P75)]表示，组间比较采用独立样本秩和检验(Mann-Whitney U)；计数资料统计描述采用百分率表示，组间比较采用c<sup>2</sup>检验；采用Spearman相关性分析探索PLR、MLR与其他临床指标的相关性；采用二元Logistic回归模型，探究PLR、MLR对脓毒症患者AKI发生的预测作用，P &lt; 0.05时差异有统计学意义；绘制受试者工作特征(receiver operator characteristic, ROC)曲线，计算PLR、MLR对预测脓毒症患者发生AKI的敏感性和特异性，约登指数(敏感度 + 特异度 − 1)最大时对应的值为最佳截断值，P &lt; 0.05时差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 一般临床资料比较</title><p>221例脓毒症患者中，95例(43%)合并AKI，126例(57%)不合并AKI，脓毒性休克患者62例，比例为28.1%。</p><p>AKI组与N-AKI组患者在性别、年龄、平均动脉压的比较上，差异均无统计学意义(P &gt; 0.05)。但脓毒性休克患者在两组中所占比例，AKI组[35例(36.8%)]明显高于N-AKI组[27例(21.4%)]，差异有统计学意义(P &lt; 0.05)，见表1。</p></sec><sec id="s7_2"><title>3.2. 实验室化验指标比较</title><p>在肾功能相关指标的比较上，AKI组血尿素氮高于N-AKI组，差异有统计学意义(P &lt; 0.01)，AKI组血肌酐高于N-AKI组，差异有统计学意义(P &lt; 0.001)。在感染相关指标的比较上，两组间白细胞计数、中性粒细胞计数、单核细胞计数、淋巴细胞计数差异无统计学意义(P &gt; 0.05)，但AKI组血小板计数小于N-AKI组，差异有统计学意义(P &lt; 0.01)，AKI组降钙素原高于N-AKI组，差异有统计学意义(P &lt; 0.01)。在血气相关指标的比较上，两组间氧合指数差异无统计学意义(P &gt; 0.05)，但AKI组动脉血pH值低于N-AKI组，差异有统计学意义(P &lt; 0.001)，AKI组动脉血乳酸高于N-AKI组，差异有统计学意义(P &lt; 0.001)。在评分系统的比较上，AKI组APACHE II评分和SOFA评分均高于N-AKI组，差异有统计学意义(P &lt; 0.001)。AKI组患者入院时PLR、入院时MLR均小于N-AKI组，差异有统计学意义(P &lt; 0.001)，入院时NLR小于N-AKI组差异有统计学意义(P &lt; 0.01)，见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of baseline data between AKI group and N-AKI grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >AKI组(n = 95)</th><th align="center" valign="middle" >N-AKI组(n = 126)</th><th align="center" valign="middle" >t/Z</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >性别(男/女)</td><td align="center" valign="middle" >67/28</td><td align="center" valign="middle" >87/39</td><td align="center" valign="middle" >−0.236</td><td align="center" valign="middle" >0.813</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >56.49 &#177; 13.65</td><td align="center" valign="middle" >55.02 &#177; 13.22</td><td align="center" valign="middle" >0.807</td><td align="center" valign="middle" >0.420</td></tr><tr><td align="center" valign="middle" >脓毒性休克(例，%)</td><td align="center" valign="middle" >35，36.8</td><td align="center" valign="middle" >27，21.4</td><td align="center" valign="middle" >−2.519</td><td align="center" valign="middle" >0.012</td></tr><tr><td align="center" valign="middle" >平均动脉压(mmHg)</td><td align="center" valign="middle" >90.45 &#177; 21.01</td><td align="center" valign="middle" >89.10 &#177; 15.26</td><td align="center" valign="middle" >0.529</td><td align="center" valign="middle" >0.598</td></tr><tr><td align="center" valign="middle" >血尿素氮(mmol/L)</td><td align="center" valign="middle" >7.68 (5.30, 12.69)</td><td align="center" valign="middle" >6.30 (5.03, 8.52)</td><td align="center" valign="middle" >−2.741</td><td align="center" valign="middle" >0.006</td></tr><tr><td align="center" valign="middle" >血肌酐(&#181;mmol/L)</td><td align="center" valign="middle" >91.00 (74.10, 149.61)</td><td align="center" valign="middle" >60.67 (48.15, 71.55)</td><td align="center" valign="middle" >−7.992</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >白细胞计数(&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >12.96 &#177; 5.82</td><td align="center" valign="middle" >12.60 &#177; 5.95</td><td align="center" valign="middle" >0.449</td><td align="center" valign="middle" >0.654</td></tr><tr><td align="center" valign="middle" >单核细胞计数(&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >0.45 (0.26, 1.00)</td><td align="center" valign="middle" >0.56 (0.33, 0.89)</td><td align="center" valign="middle" >−1.392</td><td align="center" valign="middle" >0.164</td></tr><tr><td align="center" valign="middle" >淋巴细胞计数(&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >0.86 (0.57, 1.24)</td><td align="center" valign="middle" >0.87 (0.59, 1.16)</td><td align="center" valign="middle" >−0.129</td><td align="center" valign="middle" >0.889</td></tr><tr><td align="center" valign="middle" >血小板计数(&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >172.58 &#177; 77.73</td><td align="center" valign="middle" >210.00 &#177; 106.44</td><td align="center" valign="middle" >−3.020</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >降钙素原(ng/ml)</td><td align="center" valign="middle" >1.41 (0.18, 9.65)</td><td align="center" valign="middle" >0.43 (0.13, 1.42)</td><td align="center" valign="middle" >−3.045</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >动脉血pH值</td><td align="center" valign="middle" >7.37 &#177; 0.11</td><td align="center" valign="middle" >7.44 &#177; 0.08</td><td align="center" valign="middle" >−4.865</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >动脉血乳酸(mmol/L)</td><td align="center" valign="middle" >2.00 (1.40, 3.80)</td><td align="center" valign="middle" >1.30 (1.00, 1.80)</td><td align="center" valign="middle" >−5.283</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >氧合指数(mmHg)</td><td align="center" valign="middle" >247.05 &#177; 134.49</td><td align="center" valign="middle" >269.68 &#177; 147.86</td><td align="center" valign="middle" >−1.186</td><td align="center" valign="middle" >0.237</td></tr><tr><td align="center" valign="middle" >APACHEII评分</td><td align="center" valign="middle" >18.53 &#177; 6.61</td><td align="center" valign="middle" >14.45 &#177; 5.45</td><td align="center" valign="middle" >5.021</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >SOFA评分</td><td align="center" valign="middle" >8.32 &#177; 2.57</td><td align="center" valign="middle" >6.13 &#177; 2.31</td><td align="center" valign="middle" >6.657</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >入院时PLR</td><td align="center" valign="middle" >136.97 (76.51, 240.91)</td><td align="center" valign="middle" >191.45 (131.18, 356.22)</td><td align="center" valign="middle" >−3.726</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >入院时MLR</td><td align="center" valign="middle" >0.44 (0.25, 0.73)</td><td align="center" valign="middle" >0.65 (0.41, 0.96)</td><td align="center" valign="middle" >−3.520</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >入院时NLR</td><td align="center" valign="middle" >7.59 (3.76, 14.78)</td><td align="center" valign="middle" >10.20 (6.36, 17.91)</td><td align="center" valign="middle" >−2.806</td><td align="center" valign="middle" >0.005</td></tr></tbody></table></table-wrap><p>表1. AKI组与N-AKI组基线资料比较</p></sec><sec id="s7_3"><title>3.3. 临床特征比较</title><p>AKI组中的机械通气、血液净化、血管活性药物的使用率均高于N-AKI组，并且血液净化和应用血管活性药物的使用率差异有统计学意义(P &lt; 0.001)，而机械通气的使用率差异无统计学意义(P &gt; 0.05)，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of clinical features between AKI group and N-AKI grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >AKI组(n = 95)</th><th align="center" valign="middle" >N-AKI组(n = 126)</th><th align="center" valign="middle" >c<sup>2</sup></th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >机械通气(例，%)</td><td align="center" valign="middle" >88, 92.6</td><td align="center" valign="middle" >109, 86.5</td><td align="center" valign="middle" >−1.445</td><td align="center" valign="middle" >0.148</td></tr><tr><td align="center" valign="middle" >血液净化(例，%)</td><td align="center" valign="middle" >34, 35.8</td><td align="center" valign="middle" >8, 6.3</td><td align="center" valign="middle" >−5.510</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >血管活性药物应用(例，%)</td><td align="center" valign="middle" >64, 67.4</td><td align="center" valign="middle" >50, 39.7</td><td align="center" valign="middle" >−4.068</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>表2. AKI组与N-AKI组临床特征比较</p></sec><sec id="s7_4"><title>3.4. 脓毒症AKI患者PLR、MLR与其他临床指标的相关性分析</title><p>脓毒症AKI患者PLR与性别、白细胞计数、降钙素原、血肌酐、白蛋白、APACHE II评分无相关性(P &gt; 0.05)，与年龄、血尿素氮呈轻度正相关(P &lt; 0.05)，与单核细胞计数、SOFA评分呈轻度负相关(P &lt; 0.05)，与动脉血乳酸呈轻度负相关(P &lt; 0.01)；MLR与性别、年龄、单核细胞计数、降钙素原、血尿素氮、血肌酐、动脉血乳酸、APACHE II评分无相关性(P &gt; 0.05)，与白细胞计数呈轻度正相关(P &lt; 0.05)，与SOFA评分呈中度负相关(P &lt; 0.05)，见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Correlation analysis of PLR, MLR and other clinical indicators in patients with sepsis AK</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >指标</th><th align="center" valign="middle"  colspan="2"  >PLR</th><th align="center" valign="middle"  colspan="2"  >MLR</th></tr></thead><tr><td align="center" valign="middle" >r<sub>s</sub></td><td align="center" valign="middle" >P</td><td align="center" valign="middle" >r<sub>s</sub></td><td align="center" valign="middle" >P</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" >0.188</td><td align="center" valign="middle" >0.053</td><td align="center" valign="middle" >−0.022</td><td align="center" valign="middle" >0.824</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >0.225</td><td align="center" valign="middle" >0.020</td><td align="center" valign="middle" >0.119</td><td align="center" valign="middle" >0.225</td></tr><tr><td align="center" valign="middle" >白细胞计数(&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >−0.030</td><td align="center" valign="middle" >0.761</td><td align="center" valign="middle" >0.220</td><td align="center" valign="middle" >0.023</td></tr><tr><td align="center" valign="middle" >单核细胞计数(&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >−0.230</td><td align="center" valign="middle" >0.018</td><td align="center" valign="middle" >0.089</td><td align="center" valign="middle" >0.362</td></tr><tr><td align="center" valign="middle" >降钙素原(ng/ml)</td><td align="center" valign="middle" >0.004</td><td align="center" valign="middle" >0.964</td><td align="center" valign="middle" >−0.010</td><td align="center" valign="middle" >0.921</td></tr><tr><td align="center" valign="middle" >血尿素氮(mmol/L)</td><td align="center" valign="middle" >0.217</td><td align="center" valign="middle" >0.026</td><td align="center" valign="middle" >0.084</td><td align="center" valign="middle" >0.391</td></tr><tr><td align="center" valign="middle" >血肌酐(&#181;mmol/L)</td><td align="center" valign="middle" >−0.030</td><td align="center" valign="middle" >0.759</td><td align="center" valign="middle" >−0.138</td><td align="center" valign="middle" >0.159</td></tr><tr><td align="center" valign="middle" >动脉血乳酸(mmol/L)</td><td align="center" valign="middle" >−0.268</td><td align="center" valign="middle" >0.005</td><td align="center" valign="middle" >−0.047</td><td align="center" valign="middle" >0.633</td></tr><tr><td align="center" valign="middle" >白蛋白(g/L)</td><td align="center" valign="middle" >−0.058</td><td align="center" valign="middle" >0.558</td><td align="center" valign="middle" >−0.140</td><td align="center" valign="middle" >0.151</td></tr><tr><td align="center" valign="middle" >APACHEII评分</td><td align="center" valign="middle" >0.008</td><td align="center" valign="middle" >0.932</td><td align="center" valign="middle" >−0.164</td><td align="center" valign="middle" >0.092</td></tr><tr><td align="center" valign="middle" >SOFA评分</td><td align="center" valign="middle" >−0.210</td><td align="center" valign="middle" >0.031</td><td align="center" valign="middle" >−0.407</td><td align="center" valign="middle" >0.026</td></tr></tbody></table></table-wrap><p>表3. 脓毒症AKI患者PLR、MLR与其他临床指标的相关性分析</p></sec><sec id="s7_5"><title>3.5. 脓毒症AKI患者独立预测因素的Logistic回归模型结果</title><p>单因素Logistic回归分析显示，入院24小时内首次测得的血小板计数(P &lt; 0.05)、动脉血乳酸(P &lt; 0.001)、APACHE II评分(P &lt; 0.001)、SOFA评分(P &lt; 0.001)、PLR (P &lt; 0.001)、MLR (P &lt; 0.01)与脓毒症AKI的发生相关。多因素Logistic回归分析显示，动脉血乳酸(P &lt; 0.01)、APACHEII评分(P &lt; 0.01)、SOFA评分(P &lt; 0.05)、PLR (P &lt; 0.05)、MLR (P &lt; 0.05)均为脓毒症患者发生AKI的独立预测因素，见表4。</p></sec><sec id="s7_6"><title>3.6. PLR、MLR对脓毒症AKI预测性能的ROC曲线分析</title><p>ROC曲线如图1所示。表5显示，PLR预测脓毒症患者发生AKI的AUC为0.646，95%CI (0.573~0.720)，P &lt; 0.001，最佳截断值为127.875，敏感度48.4%，特异性77%。MLR预测脓毒症患者发生AKI的AUC为0.638，95%CI (0.564~0.713)，P &lt; 0.001，最佳截断值为0.455，敏感度53.7%，特异性69.8%。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Results of logistic regression model for independent predictors of AKI in patients with sepsi</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >变量</th><th align="center" valign="middle"  colspan="2"  >单因素</th><th align="center" valign="middle"  colspan="2"  >多因素</th></tr></thead><tr><td align="center" valign="middle" >OR (95%CI)</td><td align="center" valign="middle" >P</td><td align="center" valign="middle" >OR (95%CI)</td><td align="center" valign="middle" >P</td></tr><tr><td align="center" valign="middle" >脓毒性休克</td><td align="center" valign="middle" >1.842 (0.916~3.703)</td><td align="center" valign="middle" >0.086</td><td align="center" valign="middle" >0.743 (0.289~1.905)</td><td align="center" valign="middle" >0.536</td></tr><tr><td align="center" valign="middle" >血小板计数(&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >0.996 (0.992~0.999)</td><td align="center" valign="middle" >0.022</td><td align="center" valign="middle" >1.002 (0.997~1.008)</td><td align="center" valign="middle" >0.384</td></tr><tr><td align="center" valign="middle" >动脉血乳酸(mmol/L)</td><td align="center" valign="middle" >1.773 (1.339~2.346)</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >1.619 (1.163~2.255)</td><td align="center" valign="middle" >0.004</td></tr><tr><td align="center" valign="middle" >APACHEII评分</td><td align="center" valign="middle" >1.151 (1.073~1.024)</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >1.115 (1.030~1.207)</td><td align="center" valign="middle" >0.007</td></tr><tr><td align="center" valign="middle" >SOFA评分</td><td align="center" valign="middle" >1.386 (1.195~1.607)</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >1.218 (1.006~1.475)</td><td align="center" valign="middle" >0.044</td></tr><tr><td align="center" valign="middle" >入院时PLR</td><td align="center" valign="middle" >0.995 (0.992~0.998)</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.995 (0.991~0.999)</td><td align="center" valign="middle" >0.029</td></tr><tr><td align="center" valign="middle" >入院时MLR</td><td align="center" valign="middle" >0.274 (0.115~0.652)</td><td align="center" valign="middle" >0.003</td><td align="center" valign="middle" >0.205 (0.061~0.692)</td><td align="center" valign="middle" >0.011</td></tr><tr><td align="center" valign="middle" >入院时NLR</td><td align="center" valign="middle" >0.969 (0.930~1.010)</td><td align="center" valign="middle" >0.142</td><td align="center" valign="middle" >1.067 (0.992~1.146)</td><td align="center" valign="middle" >0.79</td></tr></tbody></table></table-wrap><p>表4. 脓毒症AKI患者独立预测因素的Logistic回归模型结果</p><p>图1. PLR、MLR对脓毒症AKI预测性能的ROC曲线</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Area comparison of AKI prediction index curve of sepsi</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >曲线下面积</th><th align="center" valign="middle" >95%CI</th><th align="center" valign="middle" >P</th><th align="center" valign="middle" >最佳截断值</th><th align="center" valign="middle" >敏感度</th><th align="center" valign="middle" >特异度</th></tr></thead><tr><td align="center" valign="middle" >入院时PLR</td><td align="center" valign="middle" >0.646</td><td align="center" valign="middle" >0.573~0.720</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >127.875</td><td align="center" valign="middle" >48.4%</td><td align="center" valign="middle" >77%</td></tr><tr><td align="center" valign="middle" >入院时MLR</td><td align="center" valign="middle" >0.638</td><td align="center" valign="middle" >0.564~0.713</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.455</td><td align="center" valign="middle" >53.7%</td><td align="center" valign="middle" >69.8%</td></tr></tbody></table></table-wrap><p>表5. 脓毒症AKI各预测指标曲线下面积比较</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>AKI是危重患者常见的异质性综合征，目前我们对AKI相关的病理生理机制知之甚浅，对其预防和治疗的措施有限，导致其短期和长期预后均较差。2012年KDIGO发布的AKI定义是不充分的，因为它们没有解决潜在的异质性病理生理机制 [<xref ref-type="bibr" rid="hanspub.41765-ref12">12</xref>]，这些机制一旦得到更好地理解，即可允许个体化、精准化治疗。脓毒症AKI是AKI患者中最常见的一种类型，它的生理机制更是难以捉摸 [<xref ref-type="bibr" rid="hanspub.41765-ref13">13</xref>]，因为它是根据一系列症状和临床指标进行临床诊断的。炎症机制是脓毒症AKI重要的发病机制之一，血小板在免疫调节和炎症过程中都起着重要作用，它通过诱导炎症细胞因子的释放，与不同种类的细菌和免疫细胞相互作用，包括中性粒细胞、T淋巴细胞、自然杀伤细胞和巨噬细胞，有助于炎症过程的开始或恶化 [<xref ref-type="bibr" rid="hanspub.41765-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.41765-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.41765-ref16">16</xref>]。淋巴细胞是具有不同功能和表型特征的异质性细胞群体，参与适应性免疫。淋巴细胞减少被认为是严重脓毒症死亡率的一个指标，主要是因为它激活了凋亡过程 [<xref ref-type="bibr" rid="hanspub.41765-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.41765-ref18">18</xref>]，低淋巴细胞计数在一定程度上代表了免疫和炎症反应的抑制，也被报道与炎症性疾病有关 [<xref ref-type="bibr" rid="hanspub.41765-ref19">19</xref>]。单核细胞是先天性免疫反应的重要组成部分，通过向淋巴细胞递呈抗原的方式与适应性免疫系统相连，单核细胞对各种细菌化合物的反应导致其释放促炎性细胞因子的能力降低，这可能是脓毒症诱导免疫抑制的最显著特征 [<xref ref-type="bibr" rid="hanspub.41765-ref20">20</xref>]。因此我们推断PLR、MLR是风险指标。</p><p>本次研究显示，脓毒症AKI患者的入院时的PLR、MLR均小于N-AKI组，AKI组的APACHEⅡ评分和SOFA评分均高于N-AKI组；多因素Logistic回归模型也提示PLR、MLR、APACHEII评分、SOFA评分均为脓毒症患者发生AKI的独立预测因素。ROC曲线分析提示PLR预测脓毒症患者发生AKI的最佳截断值为127.875，MLR预测脓毒症患者发生AKI的最佳截断值为0.455，均有不错的敏感度和特异性。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，PLR、MLR是脓毒症AKI独立预测因子，均有较好的敏感度和特异性，为早期检测脓毒症患者发生AKI提供了有效的信息。本研究新颖之处是可以在任何一家一级医院、二级医院、三级医院随时、简便、快捷、廉价地获取PLR和MLR，因而具有广阔的应用空间。但本研究也有局限之处：1) 本研究为单中心、回顾性研究，且样本量相对较少。2) 只记录了入院时的PLR、MLR，未动态监测PLR、MLR，故仍需要多中心、大样本的前瞻性研究进一步验证。</p></sec><sec id="s10"><title>文章引用</title><p>王 猛,姜丽莉,周 齐,李连弟. 血小板与淋巴细胞比值和单核细胞与淋巴细胞比值预测脓毒症患者发生急性肾损伤的价值Predictive Value of Platelet-to-Lymphocyte Ratio and Monocyte-to-Lymphocyte Ratio in Acute Kidney Injury of Patients with Sepsis[J]. 临床医学进展, 2021, 11(04): 1774-1781. https://doi.org/10.12677/ACM.2021.114255</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41765-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Peerapornratana, S., Manrique-Caballero, C.L., Gómez, H. and Kellum, J.A. (2019) Acute Kidney Injury from Sepsis: Current Concepts, Epidemiology, Pathophysiology, Prevention and Treatment. Kidney International, 96, 1083-1099.  
&lt;br&gt;https://doi.org/10.1016/j.kint.2019.05.026</mixed-citation></ref><ref id="hanspub.41765-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bellomo, R., Kellum, J.A., Ronco, C., Wald, R., Martensson, J., Maiden, M., et al. (2017) Acute Kidney Injury in Sepsis. Intensive Care Medicine, 43, 816-828. &lt;br&gt;https://doi.org/10.1007/s00134-017-4755-7</mixed-citation></ref><ref id="hanspub.41765-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bellomo, R., Ronco, C., Kellum, J.A., Mehta, R.L., Palevsky, P. and Acute Dialysis Quality Initiative Workgroup. (2004) Acute Renal Failure—Definition, Outcome Measures, Animal Models, Fluid Therapy and Information Technology Needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care, 8, R204-R212. &lt;br&gt;https://doi.org/10.1186/cc2872</mixed-citation></ref><ref id="hanspub.41765-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Leedahl, D.D., Frazee, E.N., Schramm, G.E., Dierkhising, R.A., Bergstralh, E.J., Chawla, L.S., et al. (2014) Derivation of Urine Output Thresholds That Identify a Very High Risk of AKI in Patients with Septic Shock. Clinical Journal of the American Society of Nephrology, 9, 1168-1174. &lt;br&gt;https://doi.org/10.2215/CJN.09360913</mixed-citation></ref><ref id="hanspub.41765-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Thomas, M.E., Blaine, C., Dawnay, A., Devonald, M.A.J., Ftouh, S., Laing, C., et al. (2015) The Definition of Acute Kidney Injury and Its Use in Practice. Kidney International, 87, 62-73. &lt;br&gt;https://doi.org/10.1038/ki.2014.328</mixed-citation></ref><ref id="hanspub.41765-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Rosen, S. and Heyman, S.N. (2001) Difficulties in Understanding Human “Acute Tubular Necrosis”: Limited Data and Flawed Animal Models. Kidney International, 60, 1220-1224. &lt;br&gt;https://doi.org/10.1046/j.1523-1755.2001.00930.x</mixed-citation></ref><ref id="hanspub.41765-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Post, E.H., Kellum, J.A., Bellomo, R. and Vincent, J.L. (2017) Renal Perfusion in Sepsis: From Macro- to Microcirculation. Kidney International, 91, 45-60. &lt;br&gt;https://doi.org/10.1016/j.kint.2016.07.032</mixed-citation></ref><ref id="hanspub.41765-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Venet, F. and Monneret, G. (2018) Advances in the Understanding and Treatment of Sepsis-Induced Immunosuppression. Nature Reviews Nephrology, 14, 121-137. &lt;br&gt;https://doi.org/10.1038/nrneph.2017.165</mixed-citation></ref><ref id="hanspub.41765-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">de Jager, C.P., van Wijk, P.T., Mathoera, R.B., de Jongh-Leuvenink, J., van der Poll, T. and Wever, P.C. (2010) Lymphocytopenia and Neutrophil-Lymphocyte Count Ratio Predict Bacteremia Better than Conventional Infection Markers in an Emergency Care Unit. Critical Care, 14, Article No. R192. &lt;br&gt;https://doi.org/10.1186/cc9309</mixed-citation></ref><ref id="hanspub.41765-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Singer, M., Deutschman, C.S., Seymour, C.W., Shankar-Hari, M., Annane, D., Bauer, M., et al. (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 315, 801-810.  
&lt;br&gt;https://doi.org/10.1001/jama.2016.0287</mixed-citation></ref><ref id="hanspub.41765-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Khwaja, A. (2012) KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clinical Practice, 120, c179-c184. &lt;br&gt;https://doi.org/10.1159/000339789</mixed-citation></ref><ref id="hanspub.41765-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Poston, J.T. and Koyner, J.L. (2019) Sepsis Associated Acute Kidney Injury. BMJ, 364, k4891.  
&lt;br&gt;https://doi.org/10.1136/bmj.k4891</mixed-citation></ref><ref id="hanspub.41765-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Angus, D.C. and van der Poll, T. (2013) Severe Sepsis and Septic Shock. New England Journal of Medicine, 369, 840-851. &lt;br&gt;https://doi.org/10.1056/NEJMra1208623</mixed-citation></ref><ref id="hanspub.41765-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kim, C.H., Kim, S.J., Lee, M.J., Kwon, Y.E., Kim, Y.L., Park, K.S., et al. (2015) An Increase in Mean Platelet Volume from Baseline Is Associated with Mortality in Patients with Severe Sepsis or Septic Shock. PLoS ONE, 10, e0119437. &lt;br&gt;https://doi.org/10.1371/journal.pone.0119437</mixed-citation></ref><ref id="hanspub.41765-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Felmet, K.A., Hall, M.W., Clark, R.S., Jaffe, R. and Carcillo, J.A. (2005) Prolonged Lymphopenia, Lymphoid Depletion, and Hypoprolactinemia in Children with Nosocomial Sepsis and Multiple Organ Failure. Journal of Immunology, 174, 3765-3772. &lt;br&gt;https://doi.org/10.4049/jimmunol.174.6.3765</mixed-citation></ref><ref id="hanspub.41765-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Lerolle, N., Nochy, D., Guérot, E., Bruneval, P., Fagon, J.-Y., Diehl, J.-L., et al. (2010) Histopathology of Septic Shock Induced Acute Kidney Injury: Apoptosis and Leukocytic Infiltration. Intensive Care Medicine, 36, 471-478.  
&lt;br&gt;https://doi.org/10.1007/s00134-009-1723-x</mixed-citation></ref><ref id="hanspub.41765-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Yilmaz, H., Cakmak, M., Inan, O., Darcin, T. and Akcay, A. (2015) Can Neutrophil-Lymphocyte Ratio Be Independent Risk Factor for Predicting Acute Kidney Injury in Patients with Severe Sepsis? Renal Failure, 37, 225-229.  
&lt;br&gt;https://doi.org/10.3109/0886022X.2014.982477</mixed-citation></ref><ref id="hanspub.41765-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Kolaczkowska, E. and Kubes, P. (2013) Neutrophil Recruitment and Function in Health and Inflammation. Nature Reviews Immunology, 13, 159-175. &lt;br&gt;https://doi.org/10.1038/nri3399</mixed-citation></ref><ref id="hanspub.41765-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Mariano, F., Cantaluppi, V., Stella, M., Mauriello Romanazzi, G., Assenzio, B., Cairo, M., et al. (2008) Circulating Plasma Factors Induce Tubular and Glomerular Alterations in Septic Burns Patients. Critical Care, 12, Article No. R42.  
&lt;br&gt;https://doi.org/10.1186/cc6848</mixed-citation></ref><ref id="hanspub.41765-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Monneret, G. and Venet, F. (2016) Sepsis-Induced Immune Alterations Monitoring by Flow Cytometry as a Promising Tool for Individualized Therapy. Cytometry Part B: Clinical Cytometry, 90, 376-386.  
&lt;br&gt;https://doi.org/10.1002/cyto.b.21270</mixed-citation></ref></ref-list></back></article>